Press release & events

05 2019

Syngeneic tumor models were becoming invaluable for preclinical development and evaluation of immuno-based therapies in

05 / 24 / 2019

Syngeneic tumor models were becoming invaluable for preclinical development and evaluation of immuno-based therapies in the presence of a functional immunocompetent system. Explicyte is providing a series of syngeneic mouse models including subcutaneous and orthotopic models, which were fully characterized in terms of their responsiveness to immune checkpoint inhibitors (ICI) and their immune infiltration features using a high throughput-compatible flow cytometry platform.

By Explicyte Press release & events Read more...
05 2019

Explicyte intensifies its efforts in translational research and will be attending the ASCO Annual Meeting 2019 in Chicag

05 / 21 / 2019

By setting new facilities within the cancer center “Institut Bergonié”, Explicyte - in addition to its preclinical research capabilities - strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.

 

By Explicyte Press release & events Read more...
04 2019

Orthotopic glioblastoma mouse model in a new shuttle session - Cost-effective & time-saving efficacy studies

04 / 23 / 2019

Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.

By Explicyte Press release & events Read more...
Eurostars Granted Project “A Novel Modified Natural Killer (NK) Cell Immunotherapy For The Treatment Of Solid Tumours” –
05 2018

Eurostars Granted Project “A Novel Modified Natural Killer (NK) Cell Immunotherapy For The Treatment Of Solid Tumours” –

05 / 17 / 2018

Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.

By Explicyte Press release & events Read more...